Denali Therapeutics Inc. - news published 235 - readings 3.255

BACK
Denali Therapeutics Inc.

Denali Therapeutics Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes to those statements included elsewhere in this report. This discussion and analysis and other parts of this repor ...

Continue reading
27.02.2025
Denali Therapeutics Inc.

Denali Therapeutics Inc.

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Form 8-K)

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., - February 27, 2025 - Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights. "In 2024, we made significant strides across our portfo ...

Continue reading
27.02.2025
Denali Therapeutics Inc.

Denali Therapeutics Inc.

Denali Therapeutics Announces Primary Analysis and Long Term Follow Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Denali Therapeutics Inc. published this content on February 06, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 06, 2025 at 16:49:09.174 .

Continue reading
06.02.2025
Denali Therapeutics Inc.

Denali Therapeutics Inc.

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases Form 8 K

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases •FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in early 2025 •Preparing for commercial launc ...

Continue reading
13.01.2025
Denali Therapeutics Inc.

Denali Therapeutics Inc.

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial Form 8 K

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial •Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeks •Overall, DNL343 was found to be safe and well tolerated •Additional analyses ...

Continue reading
07.01.2025